Author

N. Ninkovic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Nikolic· 2 shared K. Ellestad· 2 shared M. Gallo· 2 shared A. Abdelkareem· 1 shared A. Bobyn· 1 shared A. J. Mungall· 1 shared A. Murison· 1 shared B. St Croix· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Nikolic

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

macroH2A2 shapes chromatin accessibility at enhancer elements in glioblastoma to modulate a targetable self-renewal epigenetic network

A. Nikolic, A. Bobyn, F. Maule, K. Ellestad, X. Lun, M. Johnston, C. Gafuik, F. Zemp, S. Paik, N. Ninkovic, S. Marhon, P. Mehdipour, Y. Shen, D. Berger, D. Brownsey, , M. Gallo

This study identifies macroH2A2 as a regulator of chromatin accessibility at enhancers in glioblastoma, showing that inhibiting Menin increases macroH2A2 and represses self-renewal.

bioRxiv · Feb 23, 2021 · PreprintCancer Biology

High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma

M. J. Johnston, A. Nikolic, N. Ninkovic, P. Guilhamon, F. M. Cavalli, S. Seaman, F. J. Zemp, J. Lee, A. Abdelkareem, K. Ellestad, A. Murison, M. M. Kushida, F. J. Coutinho, Y. Ma, A. J. Mungall, , M. Gallo

This study uses high-resolution 3D genome maps to identify CD276 as a therapeutic target in glioblastoma stem cells, showing it can suppress self-renewal.

bioRxiv · Oct 13, 2018Cancer Biology